公开(公告)号：US20170101406A1

公开(公告)日：2017-04-13

申请号：US15287922

申请日：2016-10-07

申请人： AbbVie S.à.r.l. ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V Patel ,  Mathieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Emiel Van der Plas ,  Xueqing Wang

IPC分类号： C07D471/04 ,  A61K31/5377 ,  C07D519/00 ,  A61K31/496 ,  A61K31/541 ,  A61K31/506 ,  A61K45/06 ,  A61K31/437

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US10130622B2

公开(公告)日：2018-11-20

申请号：US15288400

申请日：2016-10-07

申请人： AbbVie S.à.r.l. ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Katja E. Conrath ,  Douglas Cyr ,  Elsa De Lemos ,  Gert Jules Hector De Wilde ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Mathieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Chris Tse ,  Steven Emiel Van der Plas ,  Xueqing Wang

IPC分类号： A61K31/437 ,  A61K31/4545 ,  C07D471/04 ,  C07D519/00 ,  A61K45/06 ,  G01N33/50

摘要： A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.

公开(公告)号：US20170101405A1

公开(公告)日：2017-04-13

申请号：US15287911

申请日：2016-10-07

申请人： AbbVie S.à.r.l ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Matthieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Em iel Van der Plas ,  Xueqing Wang ,  Ann de Blieck

IPC分类号： C07D471/04 ,  A61K31/4545 ,  A61K31/437 ,  A61K31/506 ,  A61K45/06 ,  A61K31/5377

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US09890158B2

公开(公告)日：2018-02-13

申请号：US15287911

申请日：2016-10-07

申请人： AbbVie S.à.r.l ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Matthieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Emiel Van der Plas ,  Xueqing Wang ,  Ann de Blieck

IPC分类号： C07D471/04 ,  A61K45/06 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/4545 ,  A61K31/437 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20170100386A1

公开(公告)日：2017-04-13

申请号：US15288400

申请日：2016-10-07

申请人： AbbVie S.à.r.l. ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Katja E. Conrath ,  Douglas Cyr ,  Elsa De Lemos ,  Gert Jules Hector De Wilde ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Mathieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Chris Tse ,  Steven Emiel Van der Plas ,  Xueqing Wang

IPC分类号： A61K31/4545 ,  G01N33/50 ,  A61K45/06

CPC分类号： A61K31/4545 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00 ,  G01N33/5023 ,  G01N2800/382

摘要： A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.

公开(公告)号：US20190330207A1

公开(公告)日：2019-10-31

申请号：US16444495

申请日：2019-06-18

申请人： AbbVie S.à.r.l. ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Matthieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Emiel Van der Plas ,  Xueqing Wang ,  Ann de Blieck

IPC分类号： C07D471/04 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/4545 ,  C07D519/00 ,  A61K31/437 ,  A61K31/506

摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20180105522A1

公开(公告)日：2018-04-19

申请号：US15843917

申请日：2017-12-15

申请人： AbbVie S.à.r.l. ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Matthieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Emiel Van der Plas ,  Xueqing Wang ,  Ann de Blieck

IPC分类号： C07D471/04 ,  A61K45/06 ,  A61K31/437 ,  C07D519/00 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/4545

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US10647717B2

公开(公告)日：2020-05-12

申请号：US16444495

申请日：2019-06-18

申请人： AbbVie S.à.r.l. ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Matthieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Emiel Van der Plas ,  Xueqing Wang ,  Ann de Blieck

IPC分类号： C07D471/04 ,  A61K31/437 ,  C07D519/00 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06

摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20190202823A1

公开(公告)日：2019-07-04

申请号：US16293973

申请日：2019-03-06

申请人： AbbVie S.à.r.l. ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Matthieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Emiel Van der Plas ,  Xueqing Wang ,  Ann de Blieck

IPC分类号： C07D471/04 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/4545 ,  C07D519/00 ,  A61K31/437 ,  A61K31/506

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US10259810B2

公开(公告)日：2019-04-16

申请号：US15843917

申请日：2017-12-15

申请人： AbbVie S.à.r.l. ,  Galapagos NV

发明人： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Matthieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Emiel Van der Plas ,  Xueqing Wang ,  Ann de Blieck

IPC分类号： C07D471/04 ,  A61K45/06 ,  A61K31/506 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/437 ,  C07D519/00

摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).